Therapeutic Sequencing for Relapsed/Refractory Metastatic Renal Cell Carcinoma
Sumanta K. Pal, MD, provides comprehensive insights into second-line RCC treatment approaches, discussing the evolution from first-line therapy goals, analyzing key clinical trial data (including CONTACT-03 and TiNivo-2), evaluating patient-reported outcomes, explaining individualized therapy selection factors, addressing sequencing strategies across multiple lines of treatment, offering practical guidance on adverse event management, and highlighting promising future research directions in the field.
EP. 1: Patient With Favorable-Risk mRCC and Goals of Therapy
February 20th 2025A panelist discusses how second-line therapy goals typically shift from pursuing complete remission (as in first-line treatment) to focusing more on disease control, quality of life management, and balancing treatment effectiveness with tolerability based on the patient's prior therapy experience.
Watch
EP. 2: Second-Line Therapy Options
February 20th 2025A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials including Study 205, METEOR, CONTACT-03, TIVO-3, TiNivo-2, and LITESPARK-005, which have demonstrated varying efficacy across different patient populations and prior therapies, particularly noting the impact of prior immunotherapy exposure on treatment selection and the need for careful consideration of historical trial data in the context of modern treatment paradigms.
Watch
